FIRST-LINE GEFITINIB VS CARBOPLATIN/PACLITAXEL IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: PHASE III STUDY NEJ002

被引：0
|
作者：
Osamu, Ishimoto [1 ]
Kobayashi, Kunihiko [2 ]
Inoue, Akira [3 ]
Maemondo, Makoto
Sugawara, Shunichi [1 ]
Oizumi, Satoshi [4 ]
Saijo, Yasuo [5 ]
Gemma, Akihiko [6 ]
Morita, Satoshi [7 ]
Hagiwara, Koichi
Nukiwa, Toshihiro [3 ]
机构：
[1] Sendai Kosei Hosp, Sendai, Miyagi, Japan
[2] Saitama Med Univ, Int Med Ctr, Kawagoe, Saitama, Japan
[3] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[4] Hokkaido Univ, Sch Med, Sapporo, Hokkaido 060, Japan
[5] Hirosaki Univ, Sch Med, Hirosaki, Aomori, Japan
[6] Nippon Med Sch, Tokyo, Japan
[7] Yokohama City Univ, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
10.1093/annonc/mdq560
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [41] A RANDOMIZED, PHASE 2 STUDY OF PACLITAXEL (P) AND CARBOPLATIN (C) ± CONATUMUMAB (CON) FOR FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
    Paz-Ares, L.
    Balint, B.
    de Boer, R.
    van Meerbeeck, J. P.
    Wierzbicki, R.
    Desouza, P. L.
    Galimi, F.
    Haddad, V.
    Hei, Y.
    Ramlau, R.
    ANNALS OF ONCOLOGY, 2010, 21 : 137 - 137
  • [42] The cost effectiveness of penpulimab with paclitaxel and carboplatin in first-line treatment of metastatic squamous non-small cell lung cancer
    Kaiqi Zhu
    Zhaoyi Pan
    Mengyao Qin
    Jin Huang
    Scientific Reports, 15 (1)
  • [43] Randomized, Phase III Trial of First-Line Figitumumab in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Advanced Non-Small-Cell Lung Cancer
    Langer, Corey J.
    Novello, Silvia
    Park, Keunchil
    Krzakowski, Maciej
    Karp, Daniel D.
    Mok, Tony
    Benner, Rebecca J.
    Scranton, Judith R.
    Olszanski, Anthony J.
    Jassem, Jacek
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (19) : 2059 - U109
  • [44] Design and Stratification for Phase III Trials in First-Line Non-Small Cell Lung Cancer
    Komiya, Takefumi
    Perez, Raymond P.
    Erickson, Kirsten D.
    Huang, Chao H.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S545 - S545
  • [45] FIRST-LINE GEFITINIB TREATMENT FOR ELDERLY PATIENTS WITH NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATION: MULTICENTER PHASE II TRIAL CJLSG0901
    Takahashi, K.
    Saito, H.
    Yamamoto, M.
    Kojima, E.
    Yokoyama, T.
    Sugino, Y.
    Kimura, T.
    Ogasawara, T.
    Suzuki, R.
    Hasegawa, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 434 - 434
  • [46] A study of weekly docetaxel and carboplatin as first-line chemotherapy for advanced non-small cell lung cancer
    Jiang, Haiping
    Zhang, Xiaochen
    Chen, Jing
    Zhang, Ling
    Xiong, Jianping
    Zhong, Lin
    Yu, Feng
    Qian, Jiong
    Yu, Lanfang
    Wang, Xiaoting
    Shi, Genming
    Deng, Jing
    Xu, Nong
    JOURNAL OF THORACIC DISEASE, 2014, 6 (02) : 79 - 85
  • [47] Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial
    Mok, Tony
    Cheng, Ying
    Zhou, Xiangdong
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Tsuji, Fumito
    Rosell, Rafael
    Jaime, Jesus Corral
    Migliorino, Maria Rita
    Pluzanski, Adam
    Linke, Rolf Gerhard
    Sbar, Eric
    Wang, Tao
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study
    Dechow, Tobias
    Riera-Knorrenschild, Jorge
    Hackanson, Bjoern
    Janssen, Jan
    Schulz, Holger
    Chiabudini, Marco
    Fischer von Weikersthal, Ludwig
    Budweiser, Stephan
    Nacke, Axel
    Taeuscher, Dagmar
    Welslau, Manfred
    Potthoff, Karin
    CANCER MEDICINE, 2021, 10 (22): : 8127 - 8137
  • [49] Paclitaxel and carboplatin: A phase I study in advanced non-small cell lung cancer
    Paccagnella, A
    Favaretto, A
    Oniga, F
    Ossana, L
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 76 - 79
  • [50] Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605)
    Yoshioka, H.
    Okamoto, I.
    Morita, S.
    Ando, M.
    Takeda, K.
    Seto, T.
    Yamamoto, N.
    Nakamura, S.
    Fukuoka, M.
    Nakagawa, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345